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JID VisualDx Quiz
QUESTIONS
1. What is your diagnosis?
 a. Bullous pemphigoid.
 b. Urticaria.
 c. Subacute cutaneous lupus.
 d. Erythema multiforme.
 e. Urticaria pigmentosa.
JID VisualDx Quiz: January 2015
Arsalan Shabbir1 and Robert S. Kirsner1
Journal of Investigative Dermatology (2015) 135, e24. doi:10.1038/jid.2014.473
1Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA
Image appears with permission from VisualDx.  © Logical Images, Inc.
JID and Logical Images, Inc., have cooperated to offer the JID VisualDx Quiz, 
incorporating diagnostic images from VisualDx’s vast database. Questions relate to 
the image as well as to selected articles in JID, which are listed after the questions. 
Answers will be posted as supplementary material. We hope you enjoy this challenge.
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2.  How does the ASTERIA I study differ from previous studies of omalizumab for chronic idiopathic 
urticaria?
 a. Dosing of the drug.
 b. Inclusion criteria.
 c. Duration of the study.
 d. Ability to use additional concurrent drugs.
 e. All of the above.
3.  From the results of this study, which of the following is true regarding omalizumab for chronic 
idiopathic urticaria (CIU) (choose all that apply)?
 a. Improves CIU in a dose-dependent fashion.
 b. Most clinical improvement is experienced soon after initiation.
 c. Maximal benefit was demonstrated with this study.
 d. Placebo effect is most persistent of all treatments.
 e. All of the above. 
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Answers are available as supplementary material at http://dx.doi.org/10.1038/jid.2014.473.
